Patent Grant
9226809
The invention relates to apparatus and methods for treating urinary incontinence by use of an implant to support urethral tissue.
Men, women, and children of all ages can suffer from urinary incontinence or involuntary loss of urinary control. Their lives are perpetually interrupted by thoughts of ensuring that they have ready access to a restroom. Everyday activities such as attending a theater or sporting event can become unpleasant. Sufferers often begin to avoid social situations in an effort to reduce the stress associated with their condition.
A variety of treatment options are currently available. Some of these include external devices, behavioral therapy (such as biofeedback, electrical stimulation, or Kegel exercises), prosthetic devices, and surgery. Depending on the age, medical condition, and personal preference of a patient, surgical procedures can be used to completely restore continence.
One type of surgical procedure found to be an especially successful treatment option for incontinence in both men and women, is a sling procedure. Sling procedures typically entail surgically implanting a biocompatible implant or “sling” to support the bladder neck or urethra. Sling procedures are discussed in U.S. Pat. Nos. 5,112,344; 5,611,515; 5,842,478; 5,860,425; 5,899,909; 6,039,686; 6,042,534; 6,110,101; 6,478,727; 6,638,211; and PCT Publication Nos. WO 02/39890 and WO 02/069781.
Some “pubomedial” sling procedures involve an abdominal incision and installation of a sling between the rectus fascia in the abdominal region to a position below the urethra, and back again to the rectus fascia. A conventional procedure in females is to surgically place a sling by entering the abdominal cavity through an incision in the patient's pubovaginal region.
In males, one example of a conventional method involves surgical placement of a sling by entering the abdominal cavity through an abdominal incision. Unfortunately, to access the abdominal cavity a surgeon must incise the male patient's abdominal muscles. This procedure is more time consuming and uncomfortable for the male patient.
Other methods for treating pelvic conditions involve installation of a sling below the urethra through incisions made at the inner thigh (e.g., in the perineal skin facing the obturator and in the groin), and using a tissue path extending through the obturator. These procedures can be referred to as “transobturator” methods. See, e.g., U.S. Pat. No. 6,911,003 and Published U.S. Pat. Appl. No. 2003/0171644A1, the entireties of each being incorporated herein by reference.
While abdominal and transobturator methods of treating urinary incontinence can be effective, safe, and long-lasting, there is ongoing effort toward improving these methods.
The invention relates to methods of treating urinary incontinence in males and females.
Certain embodiments of methods and implants involve placement of a tissue support portion an implant below a urethra, placement of extension portions of the implant at tissue paths that extend from a location to support the urethra in a toward an obturator foramen. A tissue path may extend and end at pelvic fascia without reaching or passing into or through the obturator foramen. In other embodiments a tissue path may extend to the obturator foramen. In still other embodiments the tissue path may extend through an obturator foramen and to an external incision at an inner thigh. The methods can involve two opposing tissue paths, as described, one on each of a left and a right side of the patient.
The implant may involve adjustable extension portions, and the methods may involve adjusting the adjustable extension portions. Alternately or in addition, the implant may be adjusted by use of an adjusting tool that can contact spaced-apart surfaces of an implant to allow contact and manipulation of the two surfaces, simultaneously, by the single tool.
Other embodiments of implants and methods can alternately or additionally involve the use of “small-diameter” insertion tools (e.g., needles) that can be passed through a tissue path (that traverses the obturator foramen) with reduced trauma to the patient.
Still other embodiments of methods of treating incontinence in a male or female patient can involve the use of a urethra-positioning tool that can position a urethra in a location and manner to improve continence, followed by fixing the urethra in that position.
In one aspect, the invention relates to an assembly for treating urinary incontinence. The assembly includes a multi-piece implant having a support portion piece and two extension portion pieces, and an adjusting tool. The support portion piece includes a tissue support portion sized and shaped for placement to support a urethra, and the extension portion pieces each include a proximal end, a distal end, and a tissue fastener. The first extension portion piece is adjustably connected to the support portion piece at a first adjustable connection. The second extension portion piece is adjustably connected to the support portion piece at a second adjustable connection. The adjusting tool includes two adjusting surfaces, the two adjusting surfaces being capable of simultaneously engaging the support portion piece to allow adjustment of a position of the extension portion piece relative to the support portion piece at the first adjustable connection, and adjustment of a position of the second extension portion piece relative to the support portion piece at the second adjustable connection.
In a related aspect, the assembly can be used to treat urinary incontinence according to methods that involve: providing the assembly; creating a medial incision in the patient; dissecting from the medial incision to tissue below a urethra; placing the tissue support portion to contact tissue to support the urethra; placing a distal end of the first extension portion in a tissue path extending toward a first obturator foramen of the patient; placing a distal end of the second extension portion in a tissue path extending toward a second obturator foramen of the patient; connecting the first extension portion piece with the support portion piece at the first adjustable connection; connecting the second extension portion piece with the support portion piece at the second adjustable connection; engaging the adjusting tool with the support portion piece, and adjusting a position of the support portion piece relative to first and second extension portion pieces.
In another aspect, the invention relates to an implant for treating urinary incontinence. The implant includes a tissue support portion sized and shaped for placement to support a urethra; two extension portions, each extension portion extending from an end of the tissue support portion; and a tissue fastener at each extension portion. Each extension portion has an adjustable length between the tissue support portion and the tissue fastener.
In a related aspect the invention relates to a method of treating urinary incontinence in a patient using this type of implant. The method includes: providing the implant; creating a medial incision in the patient; dissecting from the medial incision to tissue below a urethra; placing the tissue support portion to support the urethra; placing the tissue fastener at the first extension portion in a tissue path extending toward a first obturator foramen of the patient; placing the tissue fastener at the second extension portion in a tissue path extending toward a second obturator foramen of the patient; and adjusting a length of an extension portion.
In another aspect the invention relates to an assembly for treating urinary incontinence in a patient. The assembly includes an implant comprising a tissue support portion and two extension portions, and an insertion tool. The insertion tool has a small-diameter needle having a diameter of less than 0.09 inch, a radius of curvature at a tip at one end of the needle that is less than 0.015 inch, and a length to extend between a medial incision in a patient, and a lateral incision in a patient adjacent to an obturator foramen.
In a related aspect, the invention involves method of treating urinary incontinence, by using this assembly. The method includes: providing the assembly; creating a medial incision in the patient; dissecting from the medial incision to tissue below a urethra; placing the tissue support portion to support the urethra; attaching the extension portion to the small diameter needle; using the small-diameter needle, passing the extension portion between the medial incision and an external location adjacent to an obturator foramen, the needle and extension portion passing through an obturator foramen.
In another aspect the invention relates to a urethra-positioning tool having an elongate shaft capable of being inserted through a meatus and into a urethra to adjust a positioning of the urethra.
A related aspect of the invention relates to a method of treating urinary treating incontinence using the urethra-positioning tool. The method includes: providing the urethra-positioning tool; inserting the shaft through a meatus and into a urethra; using the urethra-positioning tool to approximate the urethra into a position to treat the incontinence; and fixing the urethra in the position to treat incontinence.
The present invention is directed to surgical instruments, assemblies, and implantable articles for treating urinary incontinence in a male or female, including stress urinary incontinence (SUI), as well as related methods Described are various features of surgical implants, surgical tools, surgical systems, surgical kits, and surgical methods, useful for installing implants for treating incontinence. An implant can be implanted in a male or a female to treat a condition such as urge incontinence, mixed incontinence, overflow incontinence, functional incontinence, and the like.
An implant can include a tissue support portion (or “support portion”) that can be used to support a urethra. Supporting a “urethra” refers to supporting tissue that includes the urethra (which can refer to the bladder neck) and that can optionally include tissue adjacent to a urethra such as bulbospongiosus muscle, corpus spongiosum, or both. According to various methods, for example, a support portion of an implant may either be placed below bulbospongiosus muscle to support both bulbospongiosus muscle and corpus spongiosum (along with the urethra), or alternately bulbospongiosus muscle may be dissected and a support portion of an implant may be placed to contact corpus spongiosum tissue (to support the urethra). During use, the tissue support portion is typically placed below the urethra, e.g., in contact with corpus spongiosum tissue, and can optionally be attached to tissue, such as with a suture.
An implant can additionally include one or more extension portion (otherwise known as “end” portions or “arms”) attached to the tissue support portion. Normally, for treating incontinence, an implant can include two opposing extension portions. Extension portions are elongate pieces of material (e.g., mesh, suture, or biologic material) that extend from the tissue support portion and either are or can be connected to the tissue support portion, and are useful to attach to anatomical features or “supportive tissue” in the pelvic region (e.g., using a self-fixating tip) to thereby provide support for the tissue support portion and the supported tissue. Generally for treating incontinence, two extension portions can extend from the opposite ends of a tissue support portion as elongate “ends,” “arms,” or “extensions,” and may attach to supportive tissue in the pelvic region by extending through a tissue path to an internal anchoring point (see, e.g., Applicant's copending U.S. patent application Ser. No. 12/223,846, filed Aug. 8, 2008, by Ogdahl, entitled SURGICAL ARTICLES AND METHODS FOR TREATING PELVIC CONDITIONS, the entirety of which is incorporated herein by reference), or may extend to an external incision, such as through an obturator foramen and through an external incision at a groin or inner thigh (see, e.g., Applicant's copending United States Patent Publication Number US 2006/0287571, the entirety of which is incorporated herein by reference).
In exemplary uses, each extension portion can extend from the location of attachment to the tissue support portion, through pelvic tissue, and optionally attached to supportive tissue within the pelvic region; optionally the extension portion can also extend to and through an external incision. For certain procedures (that do not involve external incisions) the supportive tissue can be tissue adjacent to the urethra such as pelvic fascia; tissue between the urethra and an obturator foramen such as pelvic fascia; or tissue of an obturator foramen such as obturator fascia, obturator internus muscle, obturator membrane, obturator externus muscle, etc. For alternate procedures, sometimes referred to as “transobturator”-type procedures, an extension portion can be sized to extend from the tissue support portion, through an obturator foramen, and to then exit through an external incision in a region of a groin or inner thigh, adjacent to an obturator foramen.
An implant may include portions, pieces, or sections that are synthetic or of biological material (e.g., porcine, cadaveric, etc.). Extension portions may be, e.g., a synthetic mesh such as a polypropylene mesh, a suture, a biodegradable suture, etc. The tissue support portion may be synthetic (e.g., a polypropylene mesh) or biologic. Examples of implant products that may be similar to those useful according to the present description, include those sold commercially by American Medical Systems, Inc., of Minnetonka Minn., under the trade names Apogee® and Perigee® for use in treating pelvic prolapse (including vaginal vault prolapse, cystocele, enterocele, etc.), and Sparc®, Bioarc®, and Monarc® for treating urinary incontinence.
An example of a particular type of pelvic implant is the type that includes supportive portions including or consisting of a tissue support portion and two opposing extension portions extending from the tissue support portion. An implant that has exactly two extension portions can be of the type useful for treating urinary incontinence. The term “supportive portions” refers to portions of an implant that function to support tissue after the implant has been implanted, and specifically includes extension portions and tissue support portions, and does not include optional or appurtenant features of an implant such as a sheath, tissue fastener, or self-fixating tip or other type of connector for attaching the implant to an insertion tool.
A preferred sling for placement against a corpus spongiosum for treatment of urinary incontinence in a male patient may optionally and preferably include a widened central support, for increased contact and frictional engagement with the corpus spongiosum. According to exemplary embodiments, the sling can be tensioned to approximate corpus spongiosum proximally. A widened tissue support portion can provide improved mechanical and frictional engagement between the tissue support portion and the corpus spongiosum. A widened tissue support portion provides a larger area of contact between the implant and corpus spongiosum, and can have a reduced tendency to fold or deform upon tensioning of the implant. A suture can be used to attach the tissue support portion to the corpus spongiosum to further improve the area of contact and prevent folding, such as at a location on the anterior side of the tissue support portion. A suture may also be useful to prevent movement of the tissue support portion relative to the corpus spongiosum during or after installation or tensioning. An implant for treating male urinary incontinence can optionally and preferably have a widened tissue support portion, as discussed, for example, in Assignee's copending United States Patent Publication Number US 2006/0287571 and U.S. Pat. No. 7,422,557, the entireties of these applications being incorporated herein by reference.
Dimensions of a tissue support portion can be dimensions useful to support urethra tissue for treating incontinence. A tissue support portion can be of sufficient length to support and optionally partially surround a urethra or urethra-supporting tissue. A width of a tissue support portion may optionally and preferably be greater than a width of extension portions and can be sufficiently wide to increase contact area and frictional forces between a tissue support portion and a tissue in contact with the tissue support portion. Exemplary lengths of a tissue support portion can be in the range from 0.5 to 2 inches, such as from 0.75 to 1.5 inches. Exemplary widths of a tissue support portion can be in the range from 0.4 or 0.5 to 4 centimeters, such as from 1 to 2.5 or 3 centimeters. (A tissue support portion may be part of a support portion piece that includes the tissue support portion and optionally some amount of opposing extension portions extending from ends of the tissue support portion (see, e.g.,
Dimensions of extension portions according to the invention can allow the extension portion to reach between a tissue support portion placed to support a urethra (at an end of the extension portion connected to the tissue support portion) and, either: a location at which the distal end of the extension portion attaches to supportive tissue at or about the pelvic region; or through an obturator foramen and to an external incision at a groin or inner thigh, adjacent to the obturator foramen.
According to certain methods and implants, a distal end of an extension portion, according to certain embodiments of the invention, can include a self-fixating tip that can be attached directly to pelvic tissue such as pelvic muscle, ligament, or tendon. The length of the extension portion, therefore, can be in a range that allows placement of a tissue support portion as desired to support pelvic tissue, while the self-fixating tip is installed in pelvic tissue. Exemplary lengths of an extension portion for these embodiments, measured for example between a connection or boundary between the extension portion and the tissue support portion, and a distal end of the extension portion, can be, e.g., from 0.5 to 2.75 inches, preferably from 1.0 to 2.25 inches, and the length can optionally and preferably be adjustable.
As described elsewhere herein, a length of an extension portion can optionally be fixed (i.e., the extension portion does not include any form of length-adjusting mechanism). Alternate embodiments of implants of the invention may include adjustment or tensioning mechanisms that allow a physician to alter the length of an extension portion before, during, or after implantation.
Examples of various exemplary tissue support portion embodiments are illustrated at
As shown at
As shown at
Support portion piece 20 of
Implants as described can include a tissue fastener at a distal end or a distal portion of an extension portion, which is the end or portion not attached to a tissue support portion. (The term “distal” as used herein when referring to an extension portion is the end or portion away from a connection to a tissue support portion.)
A tissue fastener at a distal end or portion of a an extension portion can be any of various types, including: a self-fixating tip that is inserted into soft tissue and frictionally retained; soft tissue anchors; biologic adhesive; a soft tissue clamp that can generally include opposing, optionally biased, jaws that close to grab tissue; and opposing male and female connector elements that engage to secure an end of an extension portion to tissue. (See International Patent Application No. PCT/US2007/014120, entitled “Surgical Implants, Tools, and Methods for Treating Pelvic Conditions, filed Jun. 15, 2007; U.S. patent application Ser. No. 12/223,846, filed Aug. 8, 2008, entitled SURGICAL ARTICLES AND METHODS FOR TREATING PELVIC CONDITIONS; U.S. patent application Ser. No. 12/669,099, filed Jan. 14, 2010, entitled PELVIC FLOOR TREATMENTS AND RELATED TOOLS AND IMPLANTS; and WO 2009/075800, the entireties of which are incorporated herein by reference.) An implant may also have one or more extension portion that does not include a tissue fastener, for example if the distal end is designed to be secured to tissue by other methods (e.g., suturing), or is intended to pass through and obturator foramen and an external incision, in which case the extension portion may optionally include a connector, dilator, or dilating connector, which connects to an elongate tool that can be used to either push or pull the connector, dilator, or dilating connector through a tissue path to an external incision.
A tissue fastener on an extension portion can be placed at and secured within internal tissue of the pelvic region to support the implant and urethra that is supported by the implant. For example a tissue fastener can be placed at muscle tissue of an obturator foramen (e.g., obturator internus muscle, obturator membrane, obturator externus muscle, fascia), or at tissue located between a urethra and an obturator foramen, e.g., pelvic fascia.
One embodiment of a tissue fastener is a self-fixating tip. A “self-fixating tip” in general can be a structure (sometimes referred to as a soft tissue anchor) connected at a distal end of an extension portion (or extension portion piece) that can be implanted into soft tissue (e.g., muscle, fascia, ligament, etc.) in a manner that will maintain the position of the self-fixating tip and support the attached implant. Exemplary self-fixating tips can also be designed to engage an end of an insertion tool (e.g., elongate needle, elongate tube, etc.) so the insertion tool can be used to push the self-fixating tip through and into tissue for implantation, preferably also through a medial incision to reach the interior of the pelvic region, e.g., at a location of an obturator foramen. The insertion tool may engage the self-fixating tip at an internal channel of the self-fixating tip, at an external location such as at an external surface of the base, at a lateral extension, or otherwise as desired, optionally in a manner to allow the insertion tool to push the self-fixating tip through an incision in a patient and through and into supportive tissue.
Exemplary self-fixating tips can include one or more lateral extensions that allow the self-fixating tip to be inserted into soft tissue and to become effectively anchored in the tissue. A lateral extension may be moveable or fixed. The size of the self-fixating tip and optional lateral extensions can be useful to penetrate and become anchored into the tissue. Exemplary self-fixating tips are described in Assignee's copending international patent application PCTUS2007/004015, filed Feb. 16, 2007, titled Surgical Articles and Methods for Treating Pelvic Conditions, the entirety of which is incorporated herein by reference. Other structures may also be useful.
According to exemplary embodiments, a self-fixating tip can have structure that includes a base having a proximal base end and a distal base end. The proximal base end can be connected (directly or indirectly, such as by a connective suture) to a distal end of an extension portion. The base extends from the proximal base end to the distal base end and can optionally include an internal channel extending from the proximal base end at least partially along a length of the base toward the distal base end. The optional internal channel can be designed to interact with (i.e., engage) a distal end of an insertion tool to allow the insertion tool to be used to place the self-fixating tip at a location within pelvic tissue of the patient. Embodiments of self-fixating tips also include one or more lateral extension extending laterally (e.g., radially) from the base, such as from a location between the proximal end and the distal end, from a location at the distal base end, or from a location at the proximal base end.
A self-fixating tip can be made out of any useful material, generally including materials that can be molded or formed to a desired structure and connected to or attached to a distal end of an extension portion of an implant. Useful materials can include plastics such as polyethylene, polypropylene, and other thermoplastic or thermoformable materials, as well as metals, ceramics, and other types of biocompatible and optionally bioabsorbable or bioresorbable materials. Exemplary bioabsorbable materials include, e.g., polyglycolic acid (PGA), polylactide (PLA), copolymers of PGA and PLA.
Optionally, an implant can include a tissue fastener at a location of a tissue support portion, or at a location along a length of an extension portion. This form of tissue fastener, sometimes referred to as a “tissue fastener” can be in the form of a reinforced (e.g., by coating, heat treating, or a reinforcing weave or strip) edge extensions, multiple layers of mesh and edge extensions in an extension portion, etc., as described, for example, at Applicant's copending U.S. Pat. No. 7,422,557, and Applicant's copending United States Patent Publication Numbers US 2006/0195011, US 2006/0195007, and US 2006/0195010, all of which are incorporated herein by reference.
Other tissue fastener can be structure that is added to a mesh or other type of tissue support portion or extension portion to increase friction between the implant (e.g., tissue support portion or extension portion) and adjacent tissue, to prevent movement after placement of the implant; i.e., to improve short-term or long-term fixation of the extension portion within tissue. Examples of tissue fastener include relatively rigid structures such as metal, plastic, or other polymeric or non-polymeric structure that may be shaped to frictionally engage soft tissue, for example to include a tine, hook, chevron, barb, arrow, etc., combinations thereof, or any structure added to an edge or surface of an extension portion to improve fixation within tissue. The structure can have any shape or form that will increase frictional force between the implant and adjacent tissue, such as one or multiple pointed surface directed along a length of an extension portion, toward the tissue support portion, and extending away from a surface or edge of the implant (e.g., extension portion). The tissue fastener can be secured to a surface or edge of an extension portion by adhesive, thermoforming, insertion into a weave of a mesh, or any other fashion that will secure the tissue fastener to increase frictional resistance between the extension portion and adjacent tissue.
The tissue fastener can be located at a position of an implant that will result in the tissue fastener being located at supportive tissue such as muscle or fascia when the implant is placed with a midline of the tissue support portion being located below a urethra. For example, a tissue fastener may be located on a tissue support portion or an extension portion of an implant, e.g., as close as 2 or 3 centimeters from a midline of a tissue support portion, and up to a distance that reaches tissue of an obturator foramen when the midline is located below a urethra, e.g., up to 7 centimeter from the midline.
Examples of various exemplary implant embodiments that include tissue fasteners are illustrated at
As shown at
According to various embodiments of implants described herein, an implant can include multiple pieces that are adjustably connected together by an adjusting engagement. A “multi-piece” implant refers to an implant that includes a “support portion piece” and one or multiple “extension portion piece” as separate pieces of the implant. An extension portion piece can be separate from a support portion piece, and the two pieces can be connected through an adjustable engagement. The support portion piece includes a tissue support portion.
An adjusting engagement may be for example a one-way adjusting engagement or a two-way adjusting engagement, that allows a portion or a segment of an implant to be moved relative to another portion or segment, and adjusted as to length, tension, or positioning. Examples of adjusting engagements are described, for example, in Applicant's copending U.S. patent application Ser. No. 12/308,436, filed Dec. 15, 2008, entitled SURGICAL IMPLANTS AND TOOLS FOR TREATING PELVIC CONDITIONS, and U.S. patent application Ser. No. 12/669,099, filed Jan. 14, 2010, entitled PELVIC FLOOR TREATMENTS AND RELATED TOOLS AND IMPLANTS, the entireties of which are incorporated herein by reference. As an example, an extension portion piece can be attached to a support portion piece at an adjusting engagement to allow adjustment of a length of extension portion.
Some adjusting engagements can allow two-way movement of one piece relative to another piece (e.g., a “two-way” adjusting engagement). This type of adjusting engagement allows movement of a segment of implant (e.g., of a segment or portion of an extension portion piece) in two directions through an adjusting engagement. The force needed to move the segment of implant in one direction is substantially equal to the force needed to move the segment in the opposite direction, and, optionally, the two-way adjusting engagement does not substantially hinder the movement of a segment of implant through the adjusting engagement with frictional surfaces such as extensions (e.g., “teeth”) extending into an aperture through which the segment of implant is moved. As an example, a two-way adjusting engagement may include an open (smooth) aperture that may be circular, oval, square, elongate, or rectangular, such as in the form of a circle, slit, or slot, etc. The aperture may optionally be reinforced by a reinforced perimeter of a shape that is similar to the aperture, such as by a fabric or a polymeric material such as a grommet (e.g., a “loose grommet” or “eyelet”), which may be circular, square, rectangular, or of any desired shape. The reinforced perimeter (e.g., grommet) defines a reinforced aperture through which a segment of implant can pass relatively freely and with the same resistance two different directions.
Other adjusting engagements may allow for one-way adjustment such as shortening of a length of an extension portion. These adjusting engagements can be referred to as “one-way” adjusting engagements, and allow adjustment of a length of an implant portion (e.g., extension portion) in one direction and not (or not easily) in an opposite direction. An exemplary one-way adjusting engagement can include an aperture through which a segment of implant (e.g., a portion of an extension portion piece) can extend, and one or multiple surfaces (e.g., extensions or teeth) that frictionally engage the segment of implant passing therethrough, e.g., by extending into or toward the aperture or otherwise contacting the segment of implant to inhibit movement of the segment of implant relative to the adjusting engagement. The one-way engagement can preferentially allow movement of the segment of implant through the aperture in one direction while inhibiting or preventing movement of the segment of implant in an opposing direction.
In use of a tissue support portion that includes a one-way adjusting engagement such as a round or rectangular grommet, a tissue fastener (e.g., a self-fixating tip) at one end of an extension portion is placed at tissue as desired, and the second (loose) end of the extension portion piece is passed through the one-way adjusting engagement. The engagement is adjusted to place the support portion piece at a desired position (length) of the extension portion piece to provide desired support to a urethra. The one-way adjusting engagement moves easily along the extension portion piece in a direction that tightens the implant against urethra tissue, and does not move easily in the opposite direction. Once placed in position below the urethra and tightened as desired, the support portion piece is prevented from moving along the extension portion piece in the direction to reduce support of the urethra. The extension portion piece may optionally be smooth, without any frictional surface, or may alternately include bumps, detents, teeth, a jagged surface, or other frictional or mechanical structure to engage opposing structure at a surface of an aperture of the one-way adjusting engagement.
In other embodiments, an extension portion piece may engage a support portion piece at a two-way adjusting engagement, and another adjusting engagement (e.g., a one-way adjusting engagement) can be used to secure final positioning of the two pieces. As an example, a segment of an extension portion piece may extend through a two-way adjusting engagement located at a support portion piece. Because the two-way adjusting engagement allows adjustment in two directions, a second adjusting element can be used to fix the extension portion piece in place relative to the support portion piece. For example, an adjusting engagement in the form of a one-way grommet can be placed on the loose end of the extension portion piece. The one-way grommet can be used to secure the positioning of the extension portion piece and support portion piece after adjustment.
In use, the tissue fastener (e.g., a self-fixating tip) located, e.g., on an extension portion, is placed at tissue as desired, and the second (loose) end of the extension portion piece is passed through the two-way adjusting engagement. The engagement is adjusted to place the support portion piece at a desired position (length) of the extension portion piece. A second adjusting engagement, e.g., a one-way grommet, is slid onto the loose end of the extension portion piece and slid along the extension portion piece to a location at the two-way adjusting engagement. The one-way adjusting engagement moves easily along the extension portion piece in the direction toward two-way adjusting engagement, and does not move easily in the opposite direction. Once placed in position near the two-way adjusting engagement of the support portion piece, the support portion piece is prevented from moving along the extension portion piece in the direction of the one-way adjusting engagement.
An example of a multi-piece implant is shown at
Another example of a multi-piece implant is shown at
An adjusting tool can include any useful structure to support the adjusting surfaces of the adjusting tool, such as a handle (optional) at a proximal end, a shaft extending from the handle, or alternate forms of support for the adjusting surfaces. An adjusting surface can be any surface that can contact or otherwise engage a surface of an implant. Optionally and preferably an adjusting surface can be a structure that defines an aperture, slot, or slit, that is sized to engage an extension portion piece (e.g., a proximal end of an extension portion piece) by threading or otherwise passing the extension portion piece through the aperture, slot, or slit, to guide or otherwise engage the extension portion piece during adjustment. Adjusting surfaces of an adjusting tool can be spaced from each other by a distance that will allow simultaneous contact with two locations on opposing sides of an implant (e.g., at opposite ends of a tissue support portion) during use of the adjusting tool to adjust the placement of the implant relative to extension portion pieces and relative to urethral tissue being supported. For example, adjusting surfaces may be located on a line that is perpendicular to an axis of a shaft of an adjusting tool, or that is perpendicular to a line parallel to an axis of a shaft of a tool, and may be spaced by a distance in the range of 0.5 to 6 centimeters, such as a distance in the range from 2 to 5 centimeters.
In certain embodiments, each of two adjusting surfaces can be located at an end of a single or of two shafts extending from a handle. In particular embodiments a single shaft may extend from a handle, two separate tines or extensions can extend in different directions from the single shaft, and one adjusting surface can be at an end of each tine (or “extension”). For example, an adjusting tool may include a handle, a single shaft, and a “yoke” fixed or movably located at a distal end of the shaft; the yoke can extend in two directions from the shaft and can include one adjusting surface at the end of each extension. A line that connects the adjusting surfaces may be located to intersect a longitudinal axis of the shaft (the shaft, shaft extensions, and adjusting surfaces are contained in a single plane), or, in alternate embodiments, a line that connects the adjusting surfaces may be located to not intersect a longitudinal axis of the shaft (the shaft, shaft extensions, and adjusting surfaces are not contained in a single plane).
The adjusting surfaces can optionally be fixed or may be moveable, e.g., relative to a shaft. The adjusting surfaces may be fixed, or may be capable of being moved relative to a shaft in a manner to allow the adjusting surfaces to contact and adjust an implant by contacting opposite ends of the implant (e.g., support portion piece) simultaneously. For example, the adjusting tool may include a handle, a single shaft, and a “yoke” that can be moved along a length of the shaft, the yoke extending in two directions from the shaft and including one adjusting surface at the end of each extension. In one embodiment, the yoke may include a central aperture at a middle or median location between the adjusting surfaces, and the central aperture can engage the shaft to allow movement between the yoke and the shaft. Other embodiments can allow for movement with alternate structures. The yoke may be straight or curved.
The distal end of the shaft may optionally be adapted to contact the urethra during adjustment, for example by having a curved (e.g., concave) surface that approximates or matches the shape of surface of urethra tissue supported by the tissue support portion of the implant being adjusted.
Referring to adjusting tool 92 at
Still referring to
As further illustrated at
Another embodiment of an adjusting tool is shown at
In use as illustrated at
Examples of another embodiment of an adjusting tool is illustrated at
Implants as described may be placed to support a urethra of a male or a female patient, by methods that involve two opposing transobturator tissue paths, as described a Applicant's U.S. Pat. No. 7,070,556 and Applicant's copending United States Patent Publication Number US 2006-0287571-A1, each of which is incorporated herein by reference in their entireties. These “transobturator” methods generally involve making two lateral incisions at the inner thigh, each near a patient's obturator foramen, and a third, medial incision at the perineum of a male patient and at vaginal tissue of a female patient. An implant (as described herein) is implanted between the medial incision and the two lateral incisions, with opposing extension portions of the implant traversing each obturator foramen.
The urethral implant may be placed using one or more tools by installing extension portions of the sling between the medial and the lateral incisions and passing through the obturator foramen. The extension portion may be passed through the tissue path by initially inserting an insertion tool (needle) at a medial incision and advancing the insertion tool toward an obturator foramen or through an obturator foramen and to an exit point at a lateral incision (this method may sometimes be referred to as an “inside-out” tissue path trajectory, because the insertion path of the insertion tool is from the medial incision to the obturator foramen or to the lateral incision). Alternately, an extension portion may be placed by initially placing an insertion tool through an external, medial incision; advancing the insertion tool medially through an obturator foramen and to a medial incision; connecting the insertion tool to an end of an extension portion; and retracting the insertion tool to pull the extension portion into place in the transobturator tissue path (this method may sometimes referred to as an “outside-in” tissue path trajectory, because the insertion path of the insertion tool is from the lateral incision to a medial incision).
In more detail, an exemplary method includes steps of creating a medial incision at the exterior perineum (in a male), creating an external lateral incision substantially adjacent the patient's obturator foramen, providing an elongate surgical instrument such as an instrument that comprises first and second regions, the instrument having substantial structure in two or three dimensions, and providing an implant for treating the incontinence (a urethral sling). The two- or three-dimensional needle may be passed between the incisions, and then the implant can be associated with the instrument, e.g., at the end of the two- or three-dimensional region. For example, the needle may be passed from the lateral incision through the obturator foramen and to the medial incision, and the implant can be associated with the tip of the needle extending from the medial incision. The needle can then be pulled back through the incisions to pull the extension portion of the implant from the medial incision, through the obturator foramen, and to the lateral incision. Alternately, the implant can be associated with the needle before passing the needle between incisions. The needle, with the extension portion of an implant associated with the needle tip, may then be passed between incisions, such as from the medial incision, through the obturator foramen, and then through the lateral incision. This can be done on both the right side and the left side of the patient.
According to certain preferred methods of treating incontinence in a male, using implants as described, an implant can be placed below a urethra to contact tissue of a corpus spongiosum (by dissecting bulbospongiosus muscle), and the urethra can be approximated to improve continence without requiring the urethra to be compressed.
As described more specifically in US 2006-0287571-A1, according to exemplary embodiments of treating incontinence using any of the implants or tools described herein, a tissue support portion of an implant can be placed in a position to approximate and support a urethra, optionally and preferably without placing compressive forces on the urethra, to effect improved continence (e.g., in a male patient). Preferably, a tissue support portion can be placed to contact tissue of a corpus spongiosum and is tensioned to cause approximation of the corpus spongiosum and urethra in a proximal direction (meaning in this instance, toward a bladder). Accordingly, embodiments of the invention generally, in a male patient, can relate to placement of a tissue support portion at a location that supports and is tensioned to proximally (toward a bladder) re-position a urethra. The implant can be tensioned to cause the urethra—especially the posterior portion of urethra above a perineal membrane—to be moved from an abnormal (e.g., prolapsed or descended) position to a position of normal healthy urethral tissue capable of being fully coapted upon contraction of the rhabdosphincter. Alternate methods can cause compression of the urethra, but compression is not required in methods that result in approximation of the urethra to improve continence.
According to these embodiments, a method of surgically installing a urethral implant can include providing a medial incision at the perineum of a male patient to expose bulbospongiosus muscle, optionally and preferably dissecting through bulbospongiosus muscle to expose corpus spongiosum, and placing a tissue support portion of the implant to contact the corpus spongiosum tissue. Optionally the tissue support portion can be fixed to the corpus spongiosum, such as by use of a medical attachment in the form of a suture, staple, adhesive, or the like. The implant can be adjusted, tensioned, etc., e.g. based on the use of an adjusting engagement, an adjustment tool, or both, to approximate the urethra to improve continence, and tension can optionally and preferably maintained chronically.
In alternate implantation methods in a male or female patient (still optionally and preferably in a male patient, placing a tissue support portion in contact with corpus spongiosum, and approximating a urethra without a requirement for compression of a urethra), an implant can be inserted through a medial (perineal or vaginal) incision and an extension portion of the implant can be attached to tissue of an obturator foramen, or to tissue (e.g., fascia) that lies between a urethra and tissue of an obturator foramen. According to such methods, a tissue fastener such as a self-fixating tip at a distal end or distal portion of an extension portion can be engaged at a distal end of an insertion tool (e.g. a curved elongate needle). The insertion tool can be used to place the tissue fastener and extension portion through a medial incision (of a male or female patient) and extend the tissue fastener and extension portion in a direction of an obturator foramen, e.g., to tissue of the obturator foramen or to tissue between a urethra and an obturator foramen. Features of the inventive methods, implants, and tools that are described herein can be incorporated into such a technique, such as placement of the urethral sling below a urethra at a tissue of a bulbospongiosus muscle or a corpus spongiosum, approximation of the urethra to improve continence (without the need for compression of the urethra), etc., use of an implant that includes adjustable engagements (and steps of adjusting the implant), use of an adjustment tool. This method avoids the need for lateral incisions at the inner thigh and adjacent to each opposing obturator foramen.
Embodiments of a transobturator method, e.g., in a male patient, can involve insertion needles that pass between a lateral incision and medial incision using a small-diameter needle. An example of an implant for use in this type method is shown at
According to the present description, one or more needle for placing an extension portion at a transobturator tissue path, along some or a portion of a length of the needle, may be of a “small-diameter,” e.g., less than 0.09 inch in diameter, preferably less than 0.07 or 0.06 inch in diameter. A small-diameter needle can reduce trauma to tissue, increasing patient comfort and possibly improving cure and recovery rates. The needle may be of a small-diameter along an entire length of the needle, or may be of a small-diameter (as described) at a portion of a leading end of the needle, expanding to a larger diameter at a trailing end of the needle. For example the needle may have a small-diameter, e.g., less than 0.09 inch in diameter, preferably less than 0.07 or 0.06 inch in diameter, along at least one half of its entire length, or along at least three-quarters of its entire length, or along ninety percent of its entire length, or along an entire length between a proximal end and a distal end.
Also, a leading end of the needle can include a tip that is sufficiently sharp to penetrate tissue; such a tip at a leading end of the needle can be defined as a tip that has a radius of curvature of no greater than 0.015 inch, such as a radius of curvature that is no greater than 0.010 inch. Still additionally, the small-diameter needle can preferably be of a length (including curvature, meaning an arc-length of a curved needle) that allows the needle to extend completely between the lateral incision and the medial incision: a leading end of the needle can preferably be extended from the lateral incision or the medial incision, while the trailing end has not yet entered the medial or the lateral incision (respectively). An exemplary length to allow the needle to extend completely between the incisions is a length of at least 4 inches, such as a length in the range from about 3 to about 6 inches (see length “L” of
A small-diameter needle can optionally include a handle at a proximal (trailing) end, and can optionally include an aperture or other mechanism to connect to an extension portion (e.g., suture) at either a leading end or a trailing end.
Insertion tools having small-diameter needles are illustrated at
In other embodiments of methods for treating incontinence in a male or a female, a method can incorporate the use of a urethra-positioning tool to position a urethra at a location of improved continence function, such as by approximating the urethra toward a bladder or by alleviating prolapse. After using a urethra-positioning tool to position the urethra at a location to improve continence, the method can involve fixing the urethra in place by any useful fixation techniques, such as by use of an implant (as described herein, or otherwise); by use of tissue ingrowth; by use of accelerated tissue ingrowth or scarring based on injection of a substance such as a growth factor, scarring agent, or fibrosis-inducing composition, to reduce elasticity of tissue supporting the urethra; by use of a biologic adhesive; etc. The method may also include adjustment of the location of the urethra following initial placement at the desired location. Optionally, the urethra-positioning tool can include a lumen for draining a bladder during a period over which the tool is installed to allow for fixation of the urethra.
A urethra-positioning tool can be any tool that includes an elongate shaft that is sufficiently rigid (rigid, semi-rigid) to be placed into a urethra, through a meatus, and that can be used to cause the urethra to take on the form (shape) and position of the elongate shaft. The shaft can be, for example, a solid metal or plastic rod, or may be in the form of a catheter that includes a drainage lumen. A handle at a proximal end can facilitate insertion of a distal end into a meatus and placement of the urethra-positioning tool within a urethra to position the urethra at a location of improved continence function.
The shaft can be of a length to extend from a meatus, through a urethra, and to a portion of urethra that is prolapsed and that can be adjusted to improve continence; e.g., a length can be sufficient to extend from a meatus to a bladder neck or a bladder, optionally after a prostate and prostatic portion of a urethra has been removed, e.g., a length in the range from 11 to 22 centimeters, such as from 14 to 21 centimeters. The shaft can be of a shape that is at least partially curved to approximate curves of a urethra, optionally including curves of three portions of the urethra, including the prostatic urethra, the membranous urethra, and the cavernous urethra of the penis i.e., to mimic the shape of a healthy, properly-anatomically-supported, continent urethra, or a portion thereof. For example, a distal portion of the shaft can be of a curved shape that can mimic a healthy, properly-anatomically-supported, continent, membranous or prostatic urethra, and a proximal portion of the shaft can be curved to mimic a cavernous portion of the urethra that passes through a penis; such a shaft will have a “double curve” that mimics a double curve of a healthy urethra or of a continent urethra after removal of a prostate and a portion of the prostatic urethra.
For fixing the urethra in place, after desired positioning using a urethra-positioning tool, examples of useful biologic adhesives include cyanoacrylate, as well as other known adhesives useful in biologic applications. Examples of useful scarring agents, growth factors, and fibrosis-inducing compositions, to reduce elasticity of tissue supporting the urethra, can include hydrocarbon (e.g., petroleum jelly) as described at United States Patent Application Publication Number US 2004/0076653. Some exemplary scarring agents include the category of substances called “sclerosing agents” which are normally used for sclerotherapy. Examples include sodium morrhuate, sodium solution, glucose solution, and crushed pumice. Any of these materials can be injected into tissue surrounding a urethra, such as proximal to urethra submucosa after placing the urethra into a desired position using the urethra-positioning tool—to fix the position of the urethra. The amount of time needed to achieve desired fixation can depend on the type of material injected. A biological adhesive may be capable of fixing tissue in a short time, such as minutes, hours, or days. A growth factor or scarring agent may require days or weeks to achieve fixation, during which time the urethra-positioning tool must remain in place. Optionally, if a urethra-positioning tool remains in place over an extended period, such as many hours, days, or weeks, the tool can include a drainage lumen to allow urine to pass.
Methods that do not place an implant during the fixation step can avoid the use of any incisions, i.e., can be an incision-less method of treating incontinence.
Alternate methods can involve an incision to place a positioning mechanism such as an inflatable item (e.g., an inflatable balloon or pillow) below the urethra, to adjust the position of the urethra during or after a procedure to position and fix the urethra in place. At any time after a procedure of positioning the urethra, with implantation of an inflatable balloon or pillow, the size of the inflatable balloon or pillow can be changed to adjust the position of the urethra. The size of the balloon or pillow may be adjusted, for example, by use of a hypodermic needle to pass a fluid through skin, with no incision, into or out of the inflatable item.
This application claims the benefit from International Application No. PCT/US2010/000325, which was filed on Feb. 10, 2010, which in turns claims priority under 35 USC §119(e) from U.S. Provisional Patent Application having Ser. No. 61/151,378, filed Feb. 10, 2009, by Wirbisky et al., entitled ENHANCED MALE SINGLE-INCISION SLING FOR URINARY INCONTINENCE, and from U.S. Provisional Patent Application having Ser. No. 61/151,550, filed Feb. 11, 2009, by VanDeWeghe, entitled SINGLE INCISION MALE SLING, all of which are incorporated herein by reference in their entireties.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US2010/000325 | 2/10/2010 | WO | 00 | 6/27/2011 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2010/093421 | 8/19/2010 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 2738790 | Todt et al. | Mar 1956 | A |
| 3472232 | Earl | Oct 1969 | A |
| 3580313 | McKnight | May 1971 | A |
| 3763860 | Clarke | Oct 1973 | A |
| 3858783 | Kapitanov et al. | Jan 1975 | A |
| 3995619 | Glatzer | Dec 1976 | A |
| 4172458 | Pereyra | Oct 1979 | A |
| 4235238 | Ogiu et al. | Nov 1980 | A |
| 4441497 | Paudler | Apr 1984 | A |
| 4509516 | Richmond | Apr 1985 | A |
| 4548202 | Duncan | Oct 1985 | A |
| 4632100 | Somers et al. | Dec 1986 | A |
| 4873976 | Schreiber | Oct 1989 | A |
| 4932962 | Yoon et al. | Jun 1990 | A |
| 4938760 | Burton et al. | Jul 1990 | A |
| 4969892 | Burton et al. | Nov 1990 | A |
| 4979956 | Silvestrini | Dec 1990 | A |
| 5013292 | Lemay | May 1991 | A |
| 5013316 | Goble et al. | May 1991 | A |
| 5053043 | Gottesman et al. | Oct 1991 | A |
| 5085661 | Moss | Feb 1992 | A |
| 5112344 | Petros | May 1992 | A |
| 5141520 | Goble et al. | Aug 1992 | A |
| 5149329 | Richardson | Sep 1992 | A |
| 5188636 | Fedotov | Feb 1993 | A |
| 5203864 | Phillips | Apr 1993 | A |
| 5209756 | Seedhom et al. | May 1993 | A |
| 5234438 | Semrad | Aug 1993 | A |
| 5256133 | Spitz | Oct 1993 | A |
| 5268001 | Nicholson et al. | Dec 1993 | A |
| 5269783 | Sander | Dec 1993 | A |
| 5281237 | Gimpelson | Jan 1994 | A |
| 5328077 | Lou | Jul 1994 | A |
| 5337736 | Reddy | Aug 1994 | A |
| 5354292 | Braeuer et al. | Oct 1994 | A |
| 5368595 | Lewis | Nov 1994 | A |
| 5370650 | Tovey et al. | Dec 1994 | A |
| 5370662 | Stone et al. | Dec 1994 | A |
| 5376097 | Phillips | Dec 1994 | A |
| 5383904 | Totakura et al. | Jan 1995 | A |
| 5403328 | Shallman | Apr 1995 | A |
| 5439467 | Benderev et al. | Aug 1995 | A |
| 5474518 | Velazquez | Dec 1995 | A |
| 5474543 | McKay | Dec 1995 | A |
| 5520700 | Beyar et al. | May 1996 | A |
| 5520703 | Essig | May 1996 | A |
| 5527342 | Pietrzak et al. | Jun 1996 | A |
| 5544664 | Benderev et al. | Aug 1996 | A |
| 5562689 | Green et al. | Oct 1996 | A |
| 5571139 | Jenkins, Jr. | Nov 1996 | A |
| 5582188 | Benderev et al. | Dec 1996 | A |
| 5584860 | Goble et al. | Dec 1996 | A |
| 5591163 | Thompson | Jan 1997 | A |
| 5591206 | Moufarrege | Jan 1997 | A |
| 5611515 | Benderev et al. | Mar 1997 | A |
| 5628756 | Barker, Jr. et al. | May 1997 | A |
| 5643320 | Lower et al. | Jul 1997 | A |
| 5647836 | Blake et al. | Jul 1997 | A |
| 5669935 | Rosenman et al. | Sep 1997 | A |
| 5674247 | Sohn | Oct 1997 | A |
| 5683349 | Makower et al. | Nov 1997 | A |
| 5690655 | Hart et al. | Nov 1997 | A |
| 5697931 | Thompson | Dec 1997 | A |
| 5709708 | Thal | Jan 1998 | A |
| 5725529 | Nicholson et al. | Mar 1998 | A |
| 5725541 | Anspach, III et al. | Mar 1998 | A |
| 5741282 | Anspach, III et al. | Apr 1998 | A |
| 5782862 | Bonutti | Jul 1998 | A |
| 5842478 | Benderev et al. | Dec 1998 | A |
| 5860425 | Benderev et al. | Jan 1999 | A |
| 5873891 | Sohn | Feb 1999 | A |
| 5899909 | Claren et al. | May 1999 | A |
| 5904692 | Steckel et al. | May 1999 | A |
| 5922026 | Chin | Jul 1999 | A |
| 5925047 | Errico et al. | Jul 1999 | A |
| 5944732 | Raulerson et al. | Aug 1999 | A |
| 5954057 | Li | Sep 1999 | A |
| 5972000 | Beyar et al. | Oct 1999 | A |
| 5980558 | Wiley | Nov 1999 | A |
| 5984927 | Wenstrom, Jr. | Nov 1999 | A |
| 5988171 | Sohn et al. | Nov 1999 | A |
| 5997554 | Thompson | Dec 1999 | A |
| 6007539 | Kirsch et al. | Dec 1999 | A |
| 6019768 | Wenstrom et al. | Feb 2000 | A |
| 6027523 | Schmieding | Feb 2000 | A |
| 6030393 | Corlew | Feb 2000 | A |
| 6036701 | Rosenman | Mar 2000 | A |
| 6039686 | Kovac | Mar 2000 | A |
| 6042534 | Gellman et al. | Mar 2000 | A |
| 6042583 | Thompson et al. | Mar 2000 | A |
| 6048351 | Gordon et al. | Apr 2000 | A |
| 6053935 | Brenneman et al. | Apr 2000 | A |
| 6056688 | Benderev et al. | May 2000 | A |
| 6099538 | Moses | Aug 2000 | A |
| 6099551 | Gabby | Aug 2000 | A |
| 6099552 | Adams | Aug 2000 | A |
| 6110101 | Tihon et al. | Aug 2000 | A |
| 6127597 | Beyar et al. | Oct 2000 | A |
| 6168611 | Rizvi | Jan 2001 | B1 |
| 6200330 | Benderev et al. | Mar 2001 | B1 |
| 6241736 | Sater et al. | Jun 2001 | B1 |
| 6245082 | Gellman et al. | Jun 2001 | B1 |
| 6264676 | Gellman et al. | Jul 2001 | B1 |
| 6273852 | Lehe et al. | Aug 2001 | B1 |
| 6319272 | Brenneman | Nov 2001 | B1 |
| 6322492 | Kovac | Nov 2001 | B1 |
| 6328744 | Harari et al. | Dec 2001 | B1 |
| 6334446 | Beyar | Jan 2002 | B1 |
| 6382214 | Raz et al. | May 2002 | B1 |
| 6387041 | Harari et al. | May 2002 | B1 |
| 6406423 | Scetbon | Jun 2002 | B1 |
| 6406480 | Beyar et al. | Jun 2002 | B1 |
| 6423072 | Zappala | Jul 2002 | B1 |
| 6423080 | Gellman et al. | Jul 2002 | B1 |
| 6440154 | Gellman et al. | Aug 2002 | B2 |
| 6451024 | Thompson et al. | Sep 2002 | B1 |
| 6454778 | Kortenbach | Sep 2002 | B2 |
| 6475139 | Miller | Nov 2002 | B1 |
| 6478727 | Scetbon | Nov 2002 | B2 |
| 6491703 | Ulmsten | Dec 2002 | B1 |
| 6502578 | Raz et al. | Jan 2003 | B2 |
| 6506190 | Walshe | Jan 2003 | B1 |
| 6530943 | Hoepffner et al. | Mar 2003 | B1 |
| 6544273 | Harari et al. | Apr 2003 | B1 |
| 6582443 | Cabak et al. | Jun 2003 | B2 |
| 6592515 | Thierfelder | Jul 2003 | B2 |
| 6592610 | Beyar | Jul 2003 | B2 |
| 6596001 | Stormby et al. | Jul 2003 | B2 |
| 6599235 | Kovac | Jul 2003 | B2 |
| 6602260 | Harari et al. | Aug 2003 | B2 |
| 6612977 | Staskin | Sep 2003 | B2 |
| 6635058 | Beyar et al. | Oct 2003 | B2 |
| 6638210 | Berger | Oct 2003 | B2 |
| 6638211 | Suslian et al. | Oct 2003 | B2 |
| 6641525 | Rocheleau | Nov 2003 | B2 |
| 6673010 | Skiba et al. | Jan 2004 | B2 |
| 6685629 | Therin | Feb 2004 | B2 |
| 6689047 | Gellman et al. | Feb 2004 | B2 |
| 6730110 | Harari et al. | May 2004 | B1 |
| 6746455 | Beyar et al. | Jun 2004 | B2 |
| 6752814 | Gellman et al. | Jun 2004 | B2 |
| 6802807 | Anderson | Oct 2004 | B2 |
| 6884212 | Thierfelder et al. | Apr 2005 | B2 |
| 6908425 | Luscombe | Jun 2005 | B2 |
| 6908473 | Skiba et al. | Jun 2005 | B2 |
| 6911002 | Fierro | Jun 2005 | B2 |
| 6911003 | Anderson et al. | Jun 2005 | B2 |
| 6932759 | Kammerer | Aug 2005 | B2 |
| 6936052 | Gellman et al. | Aug 2005 | B2 |
| 6971986 | Staskin et al. | Dec 2005 | B2 |
| 6974462 | Sater | Dec 2005 | B2 |
| 6981983 | Rosenblatt et al. | Jan 2006 | B1 |
| 6991597 | Gellman et al. | Jan 2006 | B2 |
| 7014607 | Gellman | Mar 2006 | B2 |
| 7025772 | Gellman et al. | Apr 2006 | B2 |
| 7037255 | Inman | May 2006 | B2 |
| 7048682 | Neisz et al. | May 2006 | B2 |
| 7056333 | Walshe | Jun 2006 | B2 |
| 7070556 | Anderson | Jul 2006 | B2 |
| 7083637 | Tannhauser | Aug 2006 | B1 |
| 7087059 | Harari et al. | Aug 2006 | B2 |
| 7112171 | Rocheleau et al. | Sep 2006 | B2 |
| 7121997 | Kammerer et al. | Oct 2006 | B2 |
| 7131943 | Kammerer | Nov 2006 | B2 |
| 7223229 | Inman et al. | May 2007 | B2 |
| 7226407 | Kammerer | Jun 2007 | B2 |
| 7226408 | Harai et al. | Jun 2007 | B2 |
| 7229404 | Bouffier | Jun 2007 | B2 |
| 7229453 | Anderson | Jun 2007 | B2 |
| 7235043 | Gellman et al. | Jun 2007 | B2 |
| 7261723 | Smith et al. | Aug 2007 | B2 |
| 7267645 | Anderson et al. | Sep 2007 | B2 |
| 7291104 | Neisz et al. | Nov 2007 | B2 |
| 7297102 | Smith et al. | Nov 2007 | B2 |
| 7303525 | Watschke et al. | Dec 2007 | B2 |
| 7326213 | Benderev et al. | Feb 2008 | B2 |
| 7347812 | Mellier | Mar 2008 | B2 |
| 7351196 | Goldmann et al. | Apr 2008 | B2 |
| 7351197 | Montpetit et al. | Apr 2008 | B2 |
| 7357773 | Watschke et al. | Apr 2008 | B2 |
| 7364541 | Chu et al. | Apr 2008 | B2 |
| 7371245 | Evans et al. | May 2008 | B2 |
| 7387634 | Benderev | Jun 2008 | B2 |
| 7393320 | Montpetit et al. | Jul 2008 | B2 |
| 7407480 | Staskin | Aug 2008 | B2 |
| 7410460 | Benderev | Aug 2008 | B2 |
| 7413540 | Gellman et al. | Aug 2008 | B2 |
| 7422557 | Arnal | Sep 2008 | B2 |
| 7494495 | Delorme et al. | Feb 2009 | B2 |
| 7500945 | Cox | Mar 2009 | B2 |
| 7517313 | Thierfelder et al. | Apr 2009 | B2 |
| 7527588 | Zaddem et al. | May 2009 | B2 |
| 7527633 | Rioux | May 2009 | B2 |
| 7547316 | Priewe et al. | Jun 2009 | B2 |
| 7588598 | Delorme et al. | Sep 2009 | B2 |
| 7601118 | Smith et al. | Oct 2009 | B2 |
| 7614999 | Gellman et al. | Nov 2009 | B2 |
| 7621865 | Gellman et al. | Nov 2009 | B2 |
| 7637860 | MacLean | Dec 2009 | B2 |
| 7686759 | Sater | Mar 2010 | B2 |
| 7686760 | Anderson et al. | Mar 2010 | B2 |
| 7691050 | Gellman et al. | Apr 2010 | B2 |
| 7691052 | Gellman et al. | Apr 2010 | B2 |
| 7740576 | Hodroff | Jun 2010 | B2 |
| 7753839 | Siegel et al. | Jul 2010 | B2 |
| 7762942 | Neisz et al. | Jul 2010 | B2 |
| 7828715 | Haverfield | Nov 2010 | B2 |
| 8727963 | Knoll | May 2014 | B2 |
| 20010000533 | Kovac | Apr 2001 | A1 |
| 20010018549 | Scetbon | Aug 2001 | A1 |
| 20010027321 | Gellman et al. | Oct 2001 | A1 |
| 20010039423 | Skiba et al. | Nov 2001 | A1 |
| 20010041895 | Beyar et al. | Nov 2001 | A1 |
| 20010049467 | Lehe et al. | Dec 2001 | A1 |
| 20010053916 | Rioux | Dec 2001 | A1 |
| 20020007222 | Desai | Jan 2002 | A1 |
| 20020028980 | Thierfelder et al. | Mar 2002 | A1 |
| 20020035369 | Beyar et al. | Mar 2002 | A1 |
| 20020038119 | Weber et al. | Mar 2002 | A1 |
| 20020038132 | Abrams | Mar 2002 | A1 |
| 20020050277 | Beyar | May 2002 | A1 |
| 20020055748 | Gellman et al. | May 2002 | A1 |
| 20020058959 | Gellman et al. | May 2002 | A1 |
| 20020068948 | Stormby et al. | Jun 2002 | A1 |
| 20020077526 | Kammerer et al. | Jun 2002 | A1 |
| 20020082619 | Cabak et al. | Jun 2002 | A1 |
| 20020091373 | Berger | Jul 2002 | A1 |
| 20020095064 | Beyar | Jul 2002 | A1 |
| 20020095163 | Beyar et al. | Jul 2002 | A1 |
| 20020095181 | Beyar | Jul 2002 | A1 |
| 20020107525 | Harari et al. | Aug 2002 | A1 |
| 20020128681 | Broome et al. | Sep 2002 | A1 |
| 20020147382 | Neisz et al. | Oct 2002 | A1 |
| 20020151909 | Gellman et al. | Oct 2002 | A1 |
| 20020156487 | Gellman et al. | Oct 2002 | A1 |
| 20020156488 | Gellman et al. | Oct 2002 | A1 |
| 20020161382 | Neisz | Oct 2002 | A1 |
| 20020188169 | Kammerer et al. | Dec 2002 | A1 |
| 20030004395 | Therin | Jan 2003 | A1 |
| 20030009181 | Gellman et al. | Jan 2003 | A1 |
| 20030023136 | Raz | Jan 2003 | A1 |
| 20030023138 | Luscombe | Jan 2003 | A1 |
| 20030036676 | Scetbon | Feb 2003 | A1 |
| 20030045774 | Staskin et al. | Mar 2003 | A1 |
| 20030050530 | Neisz et al. | Mar 2003 | A1 |
| 20030065402 | Anderson et al. | Apr 2003 | A1 |
| 20030171644 | Anderson et al. | Sep 2003 | A1 |
| 20030176875 | Anderson | Sep 2003 | A1 |
| 20040015057 | Rocheleau et al. | Jan 2004 | A1 |
| 20040039453 | Anderson et al. | Feb 2004 | A1 |
| 20040193215 | Harari et al. | Sep 2004 | A1 |
| 20040225181 | Chu et al. | Nov 2004 | A1 |
| 20040267088 | Kammerer | Dec 2004 | A1 |
| 20050000523 | Beraud | Jan 2005 | A1 |
| 20050004576 | Benderev | Jan 2005 | A1 |
| 20050131391 | Chu et al. | Jun 2005 | A1 |
| 20050131393 | Chu et al. | Jun 2005 | A1 |
| 20050199249 | Karram | Sep 2005 | A1 |
| 20050245787 | Cox et al. | Nov 2005 | A1 |
| 20050256530 | Petros | Nov 2005 | A1 |
| 20050277806 | Cristalli | Dec 2005 | A1 |
| 20050278037 | Delorme et al. | Dec 2005 | A1 |
| 20050283189 | Rosenblatt et al. | Dec 2005 | A1 |
| 20060058578 | Browning | Mar 2006 | A1 |
| 20060089524 | Chu | Apr 2006 | A1 |
| 20060089525 | Mamo et al. | Apr 2006 | A1 |
| 20060195007 | Anderson | Aug 2006 | A1 |
| 20060195010 | Arnal et al. | Aug 2006 | A1 |
| 20060195011 | Arnal et al. | Aug 2006 | A1 |
| 20060217589 | Wan et al. | Sep 2006 | A1 |
| 20060229493 | Weiser et al. | Oct 2006 | A1 |
| 20060229596 | Weiser et al. | Oct 2006 | A1 |
| 20060252980 | Arnal et al. | Nov 2006 | A1 |
| 20060260618 | Hodroff et al. | Nov 2006 | A1 |
| 20060287571 | Gozzi | Dec 2006 | A1 |
| 20070015953 | MacLean | Jan 2007 | A1 |
| 20070078295 | landgrebe | Apr 2007 | A1 |
| 20070173864 | Chu | Jul 2007 | A1 |
| 20080039678 | Montpetit et al. | Feb 2008 | A1 |
| 20080300607 | Meade et al. | Dec 2008 | A1 |
| 20090012353 | Beyer | Jan 2009 | A1 |
| 20090182190 | Dann | Jul 2009 | A1 |
| 20090192347 | Davila et al. | Jul 2009 | A1 |
| 20090221867 | Ogdahl et al. | Sep 2009 | A1 |
| 20090221868 | Evans | Sep 2009 | A1 |
| 20100010631 | Otte et al. | Jan 2010 | A1 |
| 20100094079 | Inman | Apr 2010 | A1 |
| 20100256442 | Ogdahl et al. | Oct 2010 | A1 |
| 20110112357 | Chapman et al. | May 2011 | A1 |
| 20120253108 | Fischer | Oct 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 2002241673 | Nov 2005 | AU |
| 2404459 | Aug 2005 | CA |
| 4220283 | May 1994 | DE |
| 10211360 | Sep 2003 | DE |
| 20016866 | Mar 2007 | DE |
| 0650703 | Jun 1994 | EP |
| 0643945 | Jul 1994 | EP |
| 0632999 | Jan 1995 | EP |
| 1093758 | Apr 2001 | EP |
| 1342450 | Sep 2003 | EP |
| 2852813 | Jan 2004 | FR |
| 285217 | Oct 2004 | FR |
| 2268690 | Jan 1994 | GB |
| 2353220 | Oct 2000 | GB |
| 1225547 | Apr 1986 | SU |
| WO9310715 | Jun 1993 | WO |
| WO9319678 | Oct 1993 | WO |
| WO9511631 | May 1995 | WO |
| WO9525469 | Sep 1995 | WO |
| WO9716121 | May 1997 | WO |
| WO9730638 | Aug 1997 | WO |
| WO9747244 | Dec 1997 | WO |
| WO9819606 | May 1998 | WO |
| WO9835606 | Aug 1998 | WO |
| WO9835616 | Aug 1998 | WO |
| WO9842261 | Oct 1998 | WO |
| WO9853745 | Dec 1998 | WO |
| WO9937216 | Jul 1999 | WO |
| WO9937217 | Jul 1999 | WO |
| WO9952450 | Oct 1999 | WO |
| WO9953844 | Oct 1999 | WO |
| WO9958074 | Nov 1999 | WO |
| WO9959477 | Nov 1999 | WO |
| WO0013601 | Mar 2000 | WO |
| WO0030556 | Jun 2000 | WO |
| WO0040158 | Jul 2000 | WO |
| WO0057796 | Oct 2000 | WO |
| WO0074594 | Dec 2000 | WO |
| WO0074613 | Dec 2000 | WO |
| WO0074633 | Dec 2000 | WO |
| WO0230293 | Apr 2002 | WO |
| WO0232284 | Apr 2002 | WO |
| WO0234124 | May 2002 | WO |
| WO0239890 | May 2002 | WO |
| WO02058563 | Aug 2002 | WO |
| WO02062237 | Aug 2002 | WO |
| WO02069781 | Sep 2002 | WO |
| WO02071953 | Sep 2002 | WO |
| WO03013392 | Feb 2003 | WO |
| WO03017848 | Mar 2003 | WO |
| WO03034939 | May 2003 | WO |
| WO03047435 | Jun 2003 | WO |
| WO03068107 | Aug 2003 | WO |
| WO03075792 | Sep 2003 | WO |
| WO03086205 | Oct 2003 | WO |
| WO03092546 | Nov 2003 | WO |
| WO03096928 | Nov 2003 | WO |
| WO03096929 | Nov 2003 | WO |
| WO2004016196 | Feb 2004 | WO |
| WO 2004019786 | Mar 2004 | WO |
| WO2004034912 | Apr 2004 | WO |
| WO2005004727 | Jan 2005 | WO |
| WO2005046511 | May 2005 | WO |
| WO2005048850 | Jun 2005 | WO |
| WO2005079702 | Sep 2005 | WO |
| WO2005122954 | Dec 2005 | WO |
| WO2006007189 | Jan 2006 | WO |
| WO2006007190 | Jan 2006 | WO |
| WO2006031879 | Mar 2006 | WO |
| WO2006069078 | Jun 2006 | WO |
| WO2006108145 | Oct 2006 | WO |
| WO2007002012 | Jan 2007 | WO |
| WO2007002071 | Jan 2007 | WO |
| WO2007014241 | Feb 2007 | WO |
| WO2007016083 | Feb 2007 | WO |
| WO2007027592 | Mar 2007 | WO |
| WO2007059199 | May 2007 | WO |
| WO2007097994 | Aug 2007 | WO |
| WO2007137226 | Nov 2007 | WO |
| WO2007146784 | Dec 2007 | WO |
| WO2007149348 | Dec 2007 | WO |
| WO2008057261 | May 2008 | WO |
| WO2008124056 | Oct 2008 | WO |
| WO2009005714 | Jan 2009 | WO |
| WO2009017680 | Feb 2009 | WO |
| WO 2009075800 | Jun 2009 | WO |
| Entry |
|---|
| “We're staying ahead of the curve” Introducing the IVS Tunneller Device for Tension Free Procedures, Tyco Healthcare, 3 pages (2002). |
| Advantage A/T™, Surgical Mesh Sling Kit, Boston Scientific, 6 pages (2002). |
| Benderev, Theodore V., MD, A Modified Percutaneous Outpatient Bladder Neck Suspension System, Journal of Urology, vol. 152, pp. 2316-2320 (Dec. 1994). |
| Benderev, Theodore V., MD, Anchor Fixation and Other Modifications of Endoscopic Bladder Neck Suspension, Urology, vol. 40, No. 5, pp. 409-418 (Nov. 1992). |
| Capio™ CL—Transvaginal Suture Capturing Device—Transvaginal Suture Fixation to Cooper's Ligament for Sling Procedures, Boston Scientific, Microvasive®, 8 pages, (2002). |
| Cook/Ob Gyn®, Urogynecology, Copyright Cook Urological Inc., pp. 1-36 (1996). |
| Dargent, D. et al., Insertion of a Suburethral Sling Through the Obturator Membrane in the Treatment of Female Urinary Incontinence, Gynecol Obstet Fertil, vol. 30, pp. 576-582 (2002). |
| Gynecare TVT Tension-Free Support for Incontinence, The tension-free solution to female Incontinence, Gynecare Worldwide,6 pages, (2002). |
| IVS Tunneller—A Universal instrument for anterior and posterior intra-vaginal tape placement. Tyco Healthcare, 4 pages (Aug. 2002). |
| IVS Tunneller—ein universelles Instrument fur die Intra Vaginal Schlingenplastik, Tyco Healthcare, 4 pages (2001). |
| Karram, Mickey M. et al., Chapter 19 Surgical Treatment of Vaginal Vault Prolapse, Urogynecology and Reconstructive Pelvic Surgery, (Walters & Karram eds.) pp. 235-256 (Mosby 1999). |
| Kovac, S. Robert, et al, Pubic Bone Suburethral Stabilization Sling: A Long Term Cure for SUI?, Contemporary OB/GYN, 10 pages (Feb. 1998). |
| LigiSure Atlas™, Tyco Healthcare, Valleylab®, 2 pages (no date). |
| Mitek Brochure, Therapy of Urinary Stess Incontinence in Women Using Mitek GIII Anchors, by Valenzio C. Mascio, MD. |
| Pelosi, Marco Antonio III et al., Pubic Bone Suburethral Stabilization Sling: Laparoscopic Assessment of a Transvaginal Operation for the Treatment of Stress Urinary Incontinence, Journal of Laparoendoscopic & Advaned Surgical Techniques, vol. 9, No. 1 p. |
| SABRE™ Bioabsorbable Sling, Generation Now, Mentor, 4 pages (May 2002). |
| SABRE™ Surgical Procedure, Mentor, 6 pages (Aug. 2002). |
| Sanz, Luis E. et al., Modification of Abdominal Sacrocolpopexy Using a Suture Anchor System, The Journal of Reproductive Medicine, vol. 48, n. 7, pp. 496-500 (Jul. 2003). |
| Ulmsten, U. et al., An Ambulatory Surgical Procedure Under Local Anesthesia for Treatment of Female Urinary Incontinence, International Urogynecology Journal, vol. 7, pp. 81-86 (May 1996). |
| Ulmsten, Ulf et al., A Three Year Follow Up of Tension Free Vaginal Tape for Surgical Treatment of Female Stress Urinary Incontinence, British Journal of Obstetrics and Gynaecology, vol. 106, pp. 345-350 (1999). |
| Vesica® Percutaneous Bladder Neck Stabilization Kit, A New Approach to Bladder Neck Suspenison, Microvasive® Boston Scientific Corporation, 4 pages (1995). |
| Precision Twist, Low Profile design for Precise Anchor Placement, Boston Scientific Microvasive, 2001 2 pp. |
| Precision Tack, The Precise Approach to Transvaginal Sling Procedures, Boston Scientific, 1998, 4pp. |
| Number | Date | Country | |
|---|---|---|---|
| 20110288368 A1 | Nov 2011 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61151378 | Feb 2009 | US | |
| 61151550 | Feb 2009 | US |
